MetaCap

Agios Pharmaceuticals (AGIO) vs Stoke Therapeutics (STOK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Agios Pharmaceuticals (AGIO) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 9.4% versus a loss of 8.6%. Over five years, STOK leads with a +6.8% price change compared with -24.3% for AGIO. Stoke Therapeutics is the larger company by market cap ($1.75 billion vs $1.65 billion), about 1.1 times the size.

Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -764.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGIO+9.35%STOK-8.62%
+79%+26%-28%
Nov 21, 20251 yearNov 20, 2026
AGIO-27.79%STOK-3.56%
+69%-13%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGIO versus STOK key metrics
MetricAGIOSTOK
Share price$27.60$26.81
Market cap$1.65B$1.75B
1-day change-4.03%-0.45%
YTD return+1.40%-15.53%
1-year return+9.35%-8.62%
5-year return-24.28%+6.77%
EPS (TTM)$-6.31$-3.81
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$54.03M$184.42M
Revenue growth (YoY)+48.03%+404.50%
Net income (latest FY)$-412.78M$-6.88M
Gross margin88.26%—
Operating margin-873.87%-11.16%
Net margin-764.01%-3.73%
52-week high$44.09$40.22
52-week low$24.16$22.05
Distance from 52-week high-37.40%-33.34%
Analyst consensusbuystrong_buy
Avg. price target upside+67.07%+73.00%
Average volume1.06M1.02M
Shares outstanding59.81M65.41M
Employees539170
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AGIO has outperformed STOK by 18.0 percentage points over the past year.
  • Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -764.0 cents for Agios Pharmaceuticals.
  • Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs +48.03%).

About Agios Pharmaceuticals

AGIO stock →

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.

Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees

About Stoke Therapeutics

STOK stock →

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.

Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees

AGIO vs STOK FAQ

Which is bigger, Agios Pharmaceuticals or Stoke Therapeutics?

Stoke Therapeutics (STOK) is larger, with a market capitalization of $1.75B compared with $1.65B for Agios Pharmaceuticals (AGIO).

Which stock has performed better over the past year, AGIO or STOK?

AGIO returned +9.35% over the past 12 months, compared with -8.62% for STOK (price return, excluding dividends). Past performance does not predict future results.

Are Agios Pharmaceuticals and Stoke Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons